Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: Pharmacokinetics of AGA2118 in Healthy Japanese, Chinese, and Caucasian Participants
NCT07361354Phase 1Completed
- Sponsor
- Angitia Biopharmaceuticals
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AGA2118 in osteoporosis (5 cohorts), sponsored by Angitia Biopharmaceuticals. Primary endpoints: Maximum concentration at 85 days, Time to maximum concentration at 85 days and 4 more. Started Jan 2026; status: completed.
02
Drugs
AGA2118
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT07361354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361354.